The CDC's Advisory Committee on Immunization Practices (ACIP) agreed unanimously on Thursday to include the 20-valent pneumococcal conjugate vaccine (PCV20; Prevnar) as an option for U.S. children.

Pfizer’s 20-valent pneumococcal conjugate vaccine has taken a step toward approval in infants. After four doses, all 20 serotypes met the statistical noninferiority criteria in a study that compared ...

Please provide your email address to receive an email when new articles are posted on . To avoid uncertainty, an expert recommends physicians understand each vaccine’s serotypes and which ones are ...

NEW YORK--(BUSINESS WIRE)-- Pfizer today announced positive top-line results from its pivotal E.U. Phase 3 study in infants (NCT04546425) evaluating its 20-valent pneumococcal conjugate vaccine ...

Please provide your email address to receive an email when new articles are posted on . The FDA has accepted for priority review a supplemental biologics license application for Pfizer’s 20-valent ...